Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Une étude de cohorte sur la sécurité et l'efficacité du XH-02 dans le traitement de l'hypoparathyroïdie

23 septembre 2026 mis à jour par: Yan Qin, Peking Union Medical College Hospital

Une étude de cohorte élargie sur la sécurité et l'efficacité du médicament à acide nucléique ARNm XH-02 dans le traitement de l'hypoparathyroïdie adulte

XH-02 is an mRNA nucleic acid drug that expresses PTH in the body following intravenous or subcutaneous injection, providing PTH replacement therapy for patients with hypoparathyroidism. Previous clinical studies have demonstrated the safety of subcutaneously administered XH-02 in several patients with hypoparathyroidism and have yielded clear efficacy results. This study aims to further validate the safety and efficacy of subcutaneously injected XH-02 in the treatment of hypoparathyroidism in a expanded cohort.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Estimé)

60

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Beijing, Chine, 100730
        • Peking Union Medical College Hospital

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 90 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Age ≥18 years, both males and females eligible;
  2. History of postoperative chronic HP or autoimmune, genetic, or idiopathic HP for at least 26 weeks. The diagnosis of HP is established based on the presence of inappropriately low serum PTH levels concurrent with hypocalcemia in the past.
  3. Poorly controlled or intolerant to conventional treatment (calcium and vitamin D) for hypoparathyroidism;
  4. BMI 17-40 kg/m² (inclusive) at screening;
  5. If age ≤25 years, radiographic evidence of epiphyseal closure based on X-ray results of the wrist and palm of the non-dominant hand.

Exclusion Criteria:

  1. Impaired PTH response (pseudohypoparathyroidism), characterized by PTH resistance and elevated PTH levels in the presence of hypocalcemia;
  2. Allergic constitution, or allergy to the investigational drug or polyethylene glycol (PEG)-based drugs;
  3. Any disease other than HP that may affect calcium metabolism, calcium-phosphorus homeostasis, or PTH levels, such as active hyperthyroidism; Paget's disease of bone; severe hypomagnesemia; type 1 diabetes mellitus or poorly controlled type 2 diabetes mellitus (HbA1C >9%; HbA1C test results from blood samples collected within 12 weeks prior to screening are acceptable); severe and chronic liver or kidney disease; Cushing's syndrome; multiple myeloma; active pancreatitis; malnutrition; rickets; recent prolonged immobilization; active malignancy (except for low-risk well-differentiated thyroid cancer or non-melanoma skin cancer); active hyperparathyroidism; parathyroid carcinoma occurring within 5 years prior to screening; acromegaly; or multiple endocrine neoplasia;
  4. Pregnant or breastfeeding women;
  5. Male partners with female partners planning to become pregnant, or partners of childbearing potential who are unwilling to use adequate contraceptive methods during the study period;
  6. Patients with high-risk thyroid cancer requiring TSH suppression to <0.2 mIU/L within 2 years, or those with a history of tumors;
  7. Use of loop diuretics, phosphate binders (except calcium supplements), digoxin, lithium, methotrexate, biotin >30 mcg/day, or systemic corticosteroids (except as replacement therapy);
  8. Use of PTH-like drugs (whether commercially available or obtained through participation in clinical trials), including PTH(1-84), PTH(1-34), or other N-terminal fragments or analogs of PTH, or PTH-related protein within 4 weeks prior to screening;
  9. Participation in any other interventional trial receiving investigational drugs or devices within 8 weeks prior to screening, or still within 5.5 half-lives of the investigational drug from the trial in which they participated;
  10. Presence of uncontrolled hypertension at baseline, or a history of the following cardiovascular or cerebrovascular diseases, including: (1) unstable angina; (2) cardiac arrhythmias requiring medication or severe arrhythmias; (3) myocardial infarction; (4) heart failure class III or higher (NYHA classification), second-degree or higher atrioventricular block; (5) cerebral infarction (excluding lacunar infarction), cerebral hemorrhage, or other such diseases;
  11. Increased risk of osteosarcoma, such as having Paget's disease of bone or unexplained elevated alkaline phosphatase, having genetic disorders predisposing to osteosarcoma, or having a prior history of extensive external beam or implant radiation therapy involving bone;
  12. Disease processes that adversely affect gastrointestinal absorption, including but not limited to short bowel syndrome, significant small bowel resection, gastric bypass surgery, tropical sprue, active celiac disease, active ulcerative colitis, active Crohn's disease, gastroparesis, and autoimmune regulator gene mutations associated with malabsorption;
  13. Any medical or other condition that, in the investigator's judgment, may affect the conduct of the study, interfere with the study results, or increase the risk to the subject/study.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Non randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Single dose: 40 μg

Participants will receive a single subcutaneous dose of 40 μg of XH-02

Participants will receive a single dose of XH-02 through subcutaneous injection.

Expérimental: Single dose: 60 μg

Participants will receive a single subcutaneous dose of 60 μg of XH-02

Participants will receive a single dose of XH-02 through subcutaneous injection.

Expérimental: Single dose: 80 μg

Participants will receive a single subcutaneous dose of 80 μg of XH-02

Participants will receive a single dose of XH-02 through subcutaneous injection.

Expérimental: Single dose: 120 μg

Participants will receive a single subcutaneous dose of 120 μg of XH-02

Participants will receive a single dose of XH-02 through subcutaneous injection.

Expérimental: Single dose: 160 μg

Participants will receive a single subcutaneous dose of 160 μg of XH-02

Participants will receive a single dose of XH-02 through subcutaneous injection.

Expérimental: Multiple dose: 40 μg

Participants will receive 40 μg of XH-02 via subcutaneous injection daily or every other day, for a total of 5 doses.

Participants will receive XH-02 via subcutaneous injection daily or every other day, for a total of 5 doses.

Expérimental: Multiple dose: 60 μg

Participants will receive 60 μg of XH-02 via subcutaneous injection daily or every other day, for a total of 5 doses.

Participants will receive XH-02 via subcutaneous injection daily or every other day, for a total of 5 doses.

Expérimental: Multiple dose: 80 μg

Participants will receive 80 μg of XH-02 via subcutaneous injection daily or every other day, for a total of 5 doses.

Participants will receive XH-02 via subcutaneous injection daily or every other day, for a total of 5 doses.

Expérimental: Multiple dose: 120 μg

Participants will receive 120 μg of XH-02 via subcutaneous injection daily or every other day, for a total of 5 doses.

Participants will receive XH-02 via subcutaneous injection daily or every other day, for a total of 5 doses.

Expérimental: Multiple dose: 160 μg

Participants will receive 160 μg of XH-02 via subcutaneous injection daily or every other day, for a total of 5 doses.

Participants will receive XH-02 via subcutaneous injection daily or every other day, for a total of 5 doses.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Adverse events (safety)
Délai: From the first dose through 30 days after the last dose for non-serious adverse events, and through 3 months after the last dose for severe adverse events.

Adverse events, including serious adverse events. Assessment methods: spontaneous reports; scheduled laboratory tests (hematology, chemistry, C-reactive protein, urinalysis); vital signs (blood pressure, heart rate, respiratory rate, temparature), physical examinations, and electrocardiogram (QTc interval, arrhythmia).

From the first dose through 30 days after the last dose for non-serious adverse events, and through 3 months after the last dose for severe adverse events.

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
PTH(1-84) (efficacy)
Délai: Single dose: Predose (within one hour before dosing) and 4, 8, 12, 18, 24, 30, 36, 48, 60, and 72 hours postdose. Multiple dose: Predose (within one hour before each dose) and 4, 8, 12, 24, 30, 36, 48, 60, and 72 hours after the last dose.

Serum PTH(1-84)

Single dose: Predose (within one hour before dosing) and 4, 8, 12, 18, 24, 30, 36, 48, 60, and 72 hours postdose. Multiple dose: Predose (within one hour before each dose) and 4, 8, 12, 24, 30, 36, 48, 60, and 72 hours after the last dose.
PTH (efficacy)
Délai: Single dose: Predose (within one hour before dosing) and 4, 8, 12, 18, 24, 30, 36, 48, 60, and 72 hours postdose.

Serum PTH

Single dose: Predose (within one hour before dosing) and 4, 8, 12, 18, 24, 30, 36, 48, 60, and 72 hours postdose.
Serum calcium (efficacy)
Délai: Single dose: Predose (within one hour before dosing), and 4, 8, 12, 24, 36, 48, and 72 hours postdose. Multiple dose: Predose (within one hour before each dose) and 24, 48, and 72 hours after the last dose.

Serum calcium

Single dose: Predose (within one hour before dosing), and 4, 8, 12, 24, 36, 48, and 72 hours postdose. Multiple dose: Predose (within one hour before each dose) and 24, 48, and 72 hours after the last dose.
Serum phosphorus (efficacy)
Délai: Single dose: Predose (within one hour before dosing) and 4, 8, 12, 24, 36, 48, and 72 hours postdose. Multiple dose: Predose (within one hour before each dose) and 24, 48, and 72 hours after the last dose.

Serum phosphorus

Single dose: Predose (within one hour before dosing) and 4, 8, 12, 24, 36, 48, and 72 hours postdose. Multiple dose: Predose (within one hour before each dose) and 24, 48, and 72 hours after the last dose.
Serum magnesium (efficacy)
Délai: Single dose: Predose (within one hour before dosing) and 4, 8, 12, 24, 36, 48, and 72 hours postdose. Multiple dose: Predose (within one hour before each dose) and 24, 48, and 72 hours after the last dose.

Serum magnesium

Single dose: Predose (within one hour before dosing) and 4, 8, 12, 24, 36, 48, and 72 hours postdose. Multiple dose: Predose (within one hour before each dose) and 24, 48, and 72 hours after the last dose.
1, 25-Dihydroxyvitamin D3 (efficacy)
Délai: Single dose: Predose (within one hour before dosing) and 24, 48, and 72 hours postdose. Multiple dose: Predose (within one hour before the 1st, 3rd, and 5th dose) and 48 hours and 72 hours after the last dose.

Serum 1, 25-Dihydroxyvitamin D3

Single dose: Predose (within one hour before dosing) and 24, 48, and 72 hours postdose. Multiple dose: Predose (within one hour before the 1st, 3rd, and 5th dose) and 48 hours and 72 hours after the last dose.
24-hour urine calcium (efficacy)
Délai: Single dose: Predose (within 3 days before dosing), and 24, 48, and 72 hours postdose. Multiple dose: Predose (before each dose) and 24, 48, and 72 hours after the last dose.

24-hour urine calcium (24hUCa)

Single dose: Predose (within 3 days before dosing), and 24, 48, and 72 hours postdose. Multiple dose: Predose (before each dose) and 24, 48, and 72 hours after the last dose.
Fractional Excretion of calcium (efficacy)
Délai: Single dose: Predose (within one hour before dosing) and 12, 24, 36, 48, and 72 hours postdose. Multiple dose: Predose (before each dose) and 24, 48, and 72 hours after the last dose.

Fractional Excretion of calcium (FECa)

Single dose: Predose (within one hour before dosing) and 12, 24, 36, 48, and 72 hours postdose. Multiple dose: Predose (before each dose) and 24, 48, and 72 hours after the last dose.

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Procollagen type 1 N-terminal propeptide (Exploratory endpoint)
Délai: Multiple dose: Predose (within one hour before each dose) and 24, 48, and 72 hours after the last dose.

Serum Procollagen type 1 N-terminal propeptide (P1NP)

Multiple dose: Predose (within one hour before each dose) and 24, 48, and 72 hours after the last dose.
Beta-isomerized C-terminal telopeptide of type 1 collagen (Exploratory endpoint)
Délai: Multiple dose: Predose (within one hour before each dose); and 24, 48, and 72 hours after the last dose.

Serum Beta-isomerized C-terminal telopeptide of type 1 collagen (β-CTX)

Multiple dose: Predose (within one hour before each dose); and 24, 48, and 72 hours after the last dose.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Yan Qin, Peking Union Medical College Hospital

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

13 avril 2026

Achèvement primaire (Estimé)

30 avril 2030

Achèvement de l'étude (Estimé)

30 juillet 2030

Dates d'inscription aux études

Première soumission

13 avril 2026

Première soumission répondant aux critères de contrôle qualité

13 avril 2026

Première publication (Réel)

20 avril 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

28 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

23 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Description du régime IPD

The investigators do not plan to share Individual Participant Data (IPD) due to confidentiality agreements and participant privacy commitments.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner